Wockhardt (WOCKPHARMA) | Financial Analysis & Statements
Wockhardt Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
7.4B
Gross Profit
4.7B
64.23%
Operating Income
450.0M
6.10%
Net Income
-1.1B
-14.63%
EPS (Diluted)
₹-5.53
Balance Sheet Metrics
Total Assets
81.4B
Total Liabilities
34.8B
Shareholders Equity
46.6B
Debt to Equity
0.75
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Wockhardt Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 29.2B | 27.9B | 26.5B | 32.1B | 27.0B |
| Cost of Goods Sold | 11.3B | 11.6B | 11.1B | 12.7B | 11.4B |
| Gross Profit | 17.8B | 16.2B | 15.4B | 19.4B | 15.6B |
| Gross Margin % | 61.2% | 58.2% | 58.0% | 60.5% | 57.9% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 2.5B | 2.3B | 2.4B | 3.3B | 2.7B |
| Other Operating Expenses | 5.4B | 5.7B | 5.2B | 5.6B | 5.7B |
| Total Operating Expenses | 8.0B | 8.0B | 7.7B | 8.8B | 8.4B |
| Operating Income | 1.8B | -300.0M | -1.5B | 510.0M | -3.1B |
| Operating Margin % | 6.2% | -1.1% | -5.6% | 1.6% | -11.4% |
| Non-Operating Items | |||||
| Interest Income | 160.0M | 60.0M | 40.0M | 60.0M | 210.0M |
| Interest Expense | 2.5B | 2.9B | 2.9B | 2.8B | 2.4B |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -160.0M | -4.2B | -6.2B | -4.1B | -5.7B |
| Income Tax | 410.0M | 520.0M | -30.0M | -1.3B | -2.7B |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -570.0M | -4.7B | -6.2B | -2.8B | 6.9B |
| Net Margin % | -2.0% | -16.9% | -23.5% | -8.7% | 25.5% |
| Key Metrics | |||||
| EBITDA | 4.5B | 2.4B | 1.8B | 3.0B | 630.0M |
| EPS (Basic) | ₹-3.02 | ₹-32.05 | ₹-38.79 | ₹-20.24 | ₹57.11 |
| EPS (Diluted) | ₹-3.02 | ₹-32.05 | ₹-38.79 | ₹-20.24 | ₹56.88 |
| Basic Shares Outstanding | 156909209 | 144252058 | 144064321 | 120560315 | 120143716 |
| Diluted Shares Outstanding | 156909209 | 144252058 | 144064321 | 120560315 | 120143716 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Wockhardt Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.1B | 5.0B | 900.0M | 3.7B | 2.3B |
| Short-term Investments | 4.2B | 420.0M | 600.0M | 80.0M | 40.0M |
| Accounts Receivable | 6.6B | 6.2B | 8.0B | 9.2B | 9.2B |
| Inventory | 7.2B | 6.4B | 6.6B | 7.7B | 8.0B |
| Other Current Assets | 4.1B | 2.7B | 3.1B | 3.4B | 2.4B |
| Total Current Assets | 25.7B | 21.8B | 22.1B | 25.9B | 24.2B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 970.0M | 950.0M | 1.0B | 970.0M | 944.1M |
| Goodwill | 35.2B | 32.5B | 30.9B | 28.4B | 27.1B |
| Intangible Assets | 15.6B | 13.4B | 12.0B | 10.5B | 9.0B |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.1B | 1.0B | 1.1B | 1.0B | -4.4M |
| Total Non-Current Assets | 55.7B | 54.6B | 54.8B | 56.5B | 53.5B |
| Total Assets | 81.4B | 76.5B | 76.8B | 82.4B | 77.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 5.9B | 7.7B | 8.7B | 9.2B | 7.0B |
| Short-term Debt | 7.2B | 13.0B | 17.3B | 15.8B | 18.9B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 130.0M | 130.0M | 130.0M | 140.0M | 140.0M |
| Total Current Liabilities | 20.4B | 27.9B | 34.4B | 32.1B | 31.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 13.1B | 10.6B | 4.5B | 6.2B | 7.8B |
| Deferred Tax Liabilities | 350.0M | 350.0M | 320.0M | 280.0M | 280.0M |
| Other Non-Current Liabilities | 660.0M | 720.0M | 780.0M | - | - |
| Total Non-Current Liabilities | 14.4B | 12.0B | 5.9B | 8.3B | 8.9B |
| Total Liabilities | 34.8B | 39.9B | 40.2B | 40.4B | 40.2B |
| Equity | |||||
| Common Stock | 810.0M | 770.0M | 720.0M | 720.0M | 550.0M |
| Retained Earnings | 1.9B | 2.4B | 7.1B | 12.8B | 15.3B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 46.6B | 36.6B | 36.6B | 42.0B | 37.6B |
| Key Metrics | |||||
| Total Debt | 20.2B | 23.6B | 21.8B | 22.0B | 26.7B |
| Working Capital | 5.3B | -6.1B | -12.3B | -6.2B | -7.0B |
Balance Sheet Composition
Wockhardt Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -160.0M | -4.2B | -6.2B | -4.1B | 9.2B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 10.0M | 10.0M | 10.0M | 10.0M | 20.0M |
| Working Capital Changes | -4.9B | -80.0M | 1.5B | 3.7B | -1.4B |
| Operating Cash Flow | -2.9B | -1.7B | -1.8B | 2.5B | 9.9B |
| Investing Activities | |||||
| Capital Expenditures | -840.0M | 70.0M | 370.0M | -1.2B | -800.0M |
| Acquisitions | - | - | - | 0 | 15.4B |
| Investment Purchases | -4.0B | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -5.3B | 170.0M | 400.0M | -1.1B | 14.4B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | -3.5B |
| Dividends Paid | - | - | - | -20.0M | -10.0M |
| Debt Issuance | 7.3B | 4.8B | 3.3B | 16.3B | 4.1B |
| Debt Repayment | -10.7B | -4.1B | -4.1B | -20.9B | -9.6B |
| Financing Cash Flow | 2.6B | 6.1B | 30.0M | 1.9B | -8.7B |
| Free Cash Flow | -3.9B | 30.0M | -560.0M | 2.0B | -4.5B |
| Net Change in Cash | -5.6B | 4.6B | -1.3B | 3.3B | 15.6B |
Cash Flow Trend
Wockhardt Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
1,141.97
Price to Book
5.15
Price to Sales
7.42
PEG Ratio
-3.30
Profitability Ratios
Profit Margin
0.69%
Operating Margin
12.16%
Return on Equity
-1.01%
Return on Assets
-0.58%
Financial Health
Current Ratio
1.26
Debt to Equity
50.37
Beta
0.75
Per Share Data
EPS (TTM)
₹1.27
Book Value per Share
₹281.63
Revenue per Share
₹196.10
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| WOCKPHARMA | 228.3B | 1,141.97 | 5.15 | -1.01% | 0.69% | 50.37 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Dr. Reddy's | 1.1T | 19.40 | 2.94 | 16.10% | 16.36% | 18.03 |
| Lupin | 1.1T | 22.74 | 5.37 | 18.98% | 17.76% | 31.51 |
Financial data is updated regularly. All figures are in the company's reporting currency.





